Hopp til innhold
NHI.no
Annonse

Leverencefalopati: Behandling

Innhold i artikkelen

Målet med behandlingen er å bedre symptomene og forhindre at pasienten dør. Andre årsaker til bevissthetsreduksjon må utelukkes. Man må unngå å gi pasienten legemidler som demper sentralnervesystemet - det gjelder særlig benzodiazepiner (eks. Vival, Valium, Stesolid). Ofte finnes en utløsende årsak som magetarmblødning, forstoppelse, infeksjon, forstyrrelser i blodets sammensetning (elektrolytter og syrebase), inntørking - slike forhold må korrigeres.

Annonse

En viktig del av behandlingen er å redusere mengden ammonium i kroppen. For å redusere ammoniumsmengden brukes preparatet laktulose, en type avføringsmiddel. Ny kunnskap tyder på at denne behandlingen gjør at noen færre dør av tilstanden og sjansen for å utvikle alvorlige komplikasjoner som leversvikt, blødninger og infeksjon blir mindre. Det anbefales at pasienten spiser små, hyppige måltider. Ikke-absorberbare antibiotika brukes også noe. Ulempen med disse preparatene er at de er svært dyre.

Nye behandlinger er under utprøving.

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Leverencefalopati . Referanselisten for dette dokumentet vises nedenfor

  1. Ferenci P. Hepatic encephalopathy in adults: Clinical manifestations and diagnosis. UpToDate, last updated Feb 19, 2019. UpToDate
  2. Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007 Feb. 25 Suppl 1:3-9.
  3. Wolf DC. Hepatic encephalopathy. Medscape, last updated Apr 04, 2019. emedicine.medscape.com
  4. Brusilow SW, Koehler RC, Traystman RJ, and Cooper AJ. Astrocyte glutamine synthetase: importance in hyperammonemic syndromes and potential target for therapy. Neurotherapeutics, 2010; 7:452–470.
  5. Olde Damink S, Deutz N, Dejong C, Soeters P, Jalan R. Interorgan ammonia metabolism in liver failure. Neurochem Int 2002; 41: 177-88. PubMed
  6. Olde Damink S, Deutz N, Redhead D, Hayes P, Soeters P, Jalan R. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 2002; 36: 1163-71. PubMed
  7. Shawcross D, Jalan R. Dispelling myths in the treatment of hepatic encephalopathy. Lancet 2005; 365: 431-3. PubMed
  8. Cordoba J, Alonso J, Rovira A, et al. The development of low-grade cerebral oedema in cirrhosis is supported by the evolution of 1H-magnetic resonance abnormalities after liver transplantation. J Hepatol 2001; 35: 598-604. PubMed
  9. Balata S, Olde Damink S, Ferguson K, et al. Changes in neuropsychology, magnetic resonance spectroscopy and magnetization transfer following induced hyperammonemia. Hepatology 2003; 37: 931-39. PubMed
  10. Ferenci P. Hepatic encephalopathy in adults: Treatment. UpToDate, last updated Oct 21, 2019. UpToDate
  11. Cordoba J, Alonso J, Rovira A, et al. The development of low-grade cerebral oedema in cirrhosis is supported by the evolution of 1H-magnetic resonance abnormalities after liver transplantation. J Hepatol 2001; 35: 598-604. PubMed
  12. Als-Nielsen B, Gluud L, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004; 328: 1046-50. British Medical Journal
  13. Liu Q, Duan ZP, Ha dK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39: 1441-49. PubMed
  14. Cordoba J, Lopez-Hellin J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy. J Hepatol 2004; 41: 38-43. PubMed
  15. Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD003044. DOI: 10.1002/14651858.CD003044.pub4. DOI
  16. Sharma BC, Singh J, Srivastava S et al. A Randomized Controlled Trial Comparing Lactulose Plus Albumin versus Lactulose alone for Treatment of Hepatic Encephalopathy. J Gastroenterol Hepatol 2016. Epub ahead of print. pmid: 27885712 PubMed
  17. Rahimi RS, Singal AG, Cuthbert JA, et al. Lactulose vs Polyethylene Glycol 3350-Electrolyte Solution for Treatment of Overt Hepatic Encephalopathy: The HELP Randomized Clinical Trial. JAMA Intern Med. 2014 Sep 22
  18. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010 Mar 25;362(12):1071-81 PubMed
  19. Sanyal A, Younossi ZM, Bass NM, et al. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study, Aliment Pharmacol Ther 2011 Oct;34(8):853-61.
  20. Sharma BC, Sharma P, Lunia MK, et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013 Jul 23. doi: 10.1038/ajg.2013.219. DOI
Annonse
Annonse